Listen-In
Research type
Research Study
Full title
Listen-In: the development and testing of a web-based therapy application for patients with impaired speech comprehension caused by stroke.
IRAS ID
158446
Contact name
Alex Leff
Contact email
Sponsor organisation
Joint Research Office, UCL
Duration of Study in the UK
2 years, 11 months, 31 days
Research summary
The main aim is to develop and test the clinical efficacy of a novel, web-based, rehabilitation application. Listen-In will provide an effective speech comprehension training tool that patients can use to practice independently. This will free-up SALT time to provide additional assessment, supervision and functional intervention in a highly cost effective manner.
Phase 1 (24 months. London, Newcastle, Cambridge): Development of Listen-In, including diagnostic and therapeutic components, driven by patient-user's feedback (alpha and beta testing). The intervention is detailed below and is based on current SALT practice. It will be adaptive, provide feedback and target auditory perception at many levels: the phonemic, lexical and sentence level processing of heard verbal stimuli, as well as auditory short term memory and non-verbal sound discrimination.
Phase 2 (12 months. London and Cambridge): A pilot, randomised, cross-over, clinical trial of Listen-In in a group of aphasic patients in the chronic post-stroke period. A power calculation suggests that we will need 36 patents, 18 in each arm. The comparison will be standard SALT clinical care. The main outcome measure is a clinically relevant improvement on the comprehension of spoken language score of the Comprehensive Aphasia Test (Swinburn, 2004). Secondary outcomes include improvements in social activity and participation. The milestones for this phase will be: 50% recruitment into study and last-patient, last-visit.
Phase 3 (funded outside i4i grant) will be the roll-out of the therapy application on the internet with a pragmatic trial of whether therapy gains can be made outside the confines of a clinical trial. The comparison will be on similar outcome measures as Phase 2 with a control test on sustained attention (internal control) that we predict will not improve with therapy.REC name
London - Hampstead Research Ethics Committee
REC reference
15/LO/0569
Date of REC Opinion
11 May 2015
REC opinion
Further Information Favourable Opinion